The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL)

Leukemia and Lymphoma

Volumn 44, Issue SUPPL. 4, 2003, Pages

  Delaloye, Angelika Bischof ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

90Y131I; Bexxar ; NHL; Radioimmunotherapy; Zevalin

Indexed keywords

CD20 ANTIBODY; HYDROLASE; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131; TUMOR ANTIGEN; YTTRIUM 90;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA RADIATION; BLOOD TOXICITY; BODY WEIGHT; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER CELL; CELL KILLING; CLINICAL TRIAL; DISSOCIATION; DOSIMETRY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; GAMMA RADIATION; HEMATOLOGY; HOSPITAL PERSONNEL; HOSPITALIZATION; HUMAN; HYPOTHYROIDISM; ISOTOPE LABELING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MEDICINE; NURSING; ONCOLOGY; OUTPATIENT CARE; PRIORITY JOURNAL; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; SIDE EFFECT; TARGET CELL; TEAMWORK; THROMBOCYTOPENIA; THYROID GLAND; URINARY EXCRETION;

EID: 1342330126     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428140310001616935     Document Type: Article

References (36)

1. Zelenetz, A.D. (1999) "Radioimmunotherapy for lymphoma", Curr. Opin. Oncol., 11, 375-380.
2. Press, W.O. (2000) "Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma", Semin. Hematol., 37, 2-8.
3. Juweid, M.E. (2002) "Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice", J. Nucl. Med., 43, 1507-1529.
4. Safwat, A. (2000) "The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: a new look at an old method", Radiother. Oncol., 56, 1-8.
5. Horning, S.J. (1993) "Natural history of and therapy for the indolent non-Hodgkin's lymphomas", Semin. Oncol., 20, 75-88.
6. Marromatis, B.H. and Cheson, B.D. (2001) "New strategies for the treatment of indolent non-Hodgkin's lymphomas", Oncology Spectrums, 2, 706-716.
7. Hagenbeek, A. and Kluin, P.M. (1999) "Non-Hodgkin's lymphoma", In: Textbook of Malignant Haematology, edited by L. Degos, D.C. Linch, and B. Lowenberg. pp. 635-684. London: Martin Dunitz.
8. Macklis, R.M., Beresford, B.A. and Humm, J.L. (1994) "Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy", Cancer, 73, 966-973.
9. O'Donoghue, J.A. (1994) "The impact of tumor cell proliferation in radioimmunotherapy", Cancer, 73, 974-980.
10. Krasner, C. and Joyce, R.M. (2001) "Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma", Curr. Pharm. Biotechnol., 2, 341-349.
11. Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) "Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3262-3269.
12. Kaminski, M.S., Tuck, M., Regan, D., Kison, P. and Wahl, R.L. (2002) "High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar)", Blood, 100, 356a (Abstract 1381).
13. Sharkey, R.M., Motta-Hennessy, C., Gansow, O.A., Brechbiel, M.W., Fand, I., Griffiths, G. L., et al. (1990) "Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice", Int. J. Cancer, 46, 79-85.
14. Wagner, H.N., Jr., Wiseman, G.A., Marcus, C.S., Nabi, H.A., Nagle, C.E., Fink-Bennett, D.M., et al. (2002) "Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody", J. Nucl. Med., 43, 267-272.
15. Harrison, A., Walker, C.A., Parker, D., Jankowski, K.J., Cox, J.P., Craig, A.S., et al. (1991) "The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates", Int. J. Rad. Appl. Instrum. B, 18, 469-476.
16. Kozak, R.W., Raubitschek, A., Mirzadeh, S., Brechbiel, M.W., Junghans, R.P., Gansow, O.A., el al. (1989) "Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity", Cancer Res., 49, 2639-2644.
17. Casey, J.L., King, D.J., Chaplin, L.C., Haines, A.M., Pedley, R.B., Mountain, A., et al. (1996) "Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments", Br. J. Cancer, 74, 1397-1405.
18. Chinn, P.C., Leonard, J.E., Rosenberg, J., Hanna, N. and Anderson, D.R. (1999) "Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma", Int. J. Oncol., 15, 1017-1025.
19. Wiseman, G.A., Kornmehl, E., Leigh, B., Erwin, W.D., Podoloff, D.A., Spies, S., et al. (2003) "Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials", J. Nucl. Med., 44, 465-474.
20. Wiseman, G.A., Leigh, B.R. and Erwin, W.D. (2001) "Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma", J. Nucl. Med., 42, 268P.
21. Witzig, T.E., White, C.A., Gordon, L.I., Wiseman, G.A., Emmanouilides, C., Murray, J.L., et al. (2003) "Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma", J. Clin. Oncol., 21, 1263-1270.
22. Kaminski, M.S., Zasadny, K.R., Francis, I.R., Milik, A.W., Ross, C.W., Moon, S.D., et al. (1993) "Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody", N. Engl. J. Med., 329, 459-465.
23. Gates, V.L., Carey, J.E., Siegel, J.A., Kaminski, M.S. and Wahl, R.L. (1998) "Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy", J. Nucl. Med., 39, 1230-1236.
24. Mattes, M.J., Griffiths, G.L., Diril, H., Goldenberg, D.M., Ong, G.L. and Shih, L.B. (1994) "Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells", Cancer, 73, 787-793.
25. Liu, S.Y., Eary, J.F., Petersdorf, S.H., Martin, P.J., Maloney, D.G., Appelbaum, F.R., et al. (1998) "Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue", J. Clin. Oncol., 16, 3270-3278.
26. Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259-1266.
27. Letvin, N.L., Zalutsky, M.R., Lambert, J.M., Chalifoux, L.V., Nadler, L.M., Schlossman, S.F., et al. (1987) "Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys", Int. J. Rad. Appl. Instrum. B, 14, 99-105.
28. Kaminski, M.S., Fig, L.M., Zasadny, K.R., Koral, K.F., DelRosario, R.B., Francis, I.R., et al. (1992) "Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma", J. Clin. Oncol., 10, 1696-1711.
29. Kaminski, M.S., Zelenetz, A.D., Press, O.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 19, 3918-3928.
30. Davis, T.A., Kaminski, M.S., Leonnard, J.P., Gregory, S.A., Wahl, R., Hsu, F.J., et al. (2001) "Results of a randomized study of Bexxar (tositumomab and Iodine I 131 tositumomab) vs unlabelled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL)", Blood, 98, 843a (Abstract 3503).
31. Davies, A.J., Radford, J.A., Britton, K., Howell, S., Deakin, D.P., Micallef, I.N., et al. (2001) "A phase II study of Bexxar (tositumomab and I-131 tositumomab) for patients at 1st or 2nd recurrence of B-cell non Hodgkin's lymphoma", Proc. Am. Soc. Clin. Oncol., 20, 286a (Abstract 1142).
32. Wiseman, G., Leigh, B. and Witzig, T. (2001) "Radiation exposure is very low to family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma", Eur. J. Nucl. Med., 28, 1198 (Abstract PS 1479).
33. Rutar, F.J., Augustine, S.C., Colcher, D., Siegel, J.A., Jacobson, D.A., Tempero, M.A., et al. (2001) "Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members", J. Nucl. Med., 42, 907-915.
34. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 2453-2463.
35. Wiseman, G.A., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S., Bartlett, N.L., et al. (2002) "Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial", Blood, 99, 4336-4342.
36. Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, S.J., Radford, J.A., et al. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 18, 1316-1323.